Immunic (NASDAQ:IMUX) Given Outperform Rating at Wedbush

Wedbush reissued their outperform rating on shares of Immunic (NASDAQ:IMUXGet Rating) in a research report report published on Wednesday morning, MarketBeat reports. The brokerage currently has a $11.00 price objective on the stock.

A number of other brokerages have also recently commented on IMUX. Aegis reduced their target price on Immunic from $40.00 to $35.00 and set a buy rating for the company in a report on Monday, August 8th. HC Wainwright reissued a buy rating and set a $26.00 target price on shares of Immunic in a report on Monday. Finally, SVB Leerink reduced their target price on Immunic from $45.00 to $9.00 and set an outperform rating for the company in a report on Friday, June 3rd. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $24.00.

Immunic Price Performance

Shares of Immunic stock opened at $3.34 on Wednesday. The business has a 50 day simple moving average of $4.37 and a two-hundred day simple moving average of $6.21. Immunic has a 12 month low of $2.52 and a 12 month high of $14.50. The stock has a market capitalization of $102.09 million, a P/E ratio of -1.10 and a beta of 1.98.

Institutional Investors Weigh In On Immunic

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Altium Capital Management LP increased its holdings in shares of Immunic by 890.0% in the fourth quarter. Altium Capital Management LP now owns 317,000 shares of the company’s stock valued at $3,034,000 after purchasing an additional 284,979 shares during the last quarter. Parkman Healthcare Partners LLC increased its stake in Immunic by 11.8% during the first quarter. Parkman Healthcare Partners LLC now owns 1,089,251 shares of the company’s stock worth $12,309,000 after acquiring an additional 115,068 shares during the last quarter. RTW Investments LP increased its stake in Immunic by 57.7% during the first quarter. RTW Investments LP now owns 2,705,513 shares of the company’s stock worth $30,572,000 after acquiring an additional 990,043 shares during the last quarter. Soleus Capital Management L.P. acquired a new stake in Immunic during the fourth quarter worth $1,675,000. Finally, MetLife Investment Management LLC acquired a new stake in Immunic during the first quarter worth $134,000. Institutional investors and hedge funds own 59.77% of the company’s stock.

Immunic Company Profile

(Get Rating)

Immunic, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.

Read More

Analyst Recommendations for Immunic (NASDAQ:IMUX)

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.